| Literature DB >> 31537899 |
Meiling Yang1,2, Li Lin1,2, Chunli Sha1,2, Taoqiong Li1,2, Dan Zhao2, Hong Wei1, Qi Chen1, Yueqin Liu1, Xiaofang Chen2, Wenlin Xu3,4, Yuefeng Li5, Xiaolan Zhu6,7.
Abstract
Chemotherapy-induced premature ovarian failure (POF) in women is currently clinically irreversible. Bone marrow mesenchymal stem cells (BMSCs) are a promising cellular therapeutic strategy for POF. However, the underlying mechanism governing the efficacy of BMSCs in treating POF has not been determined. In this study, we show that BMSC and BMSC-derived exosome transplantation can significantly recover the estrus cycle, increase the number of basal and sinus follicles in POF rats, increase estradiol (E2) and anti-Mullerian hormone (AMH) levels, and reduce follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels in the serum. Furthermore, we demonstrate that BMSC-derived exosomes prevent ovarian follicular atresia in cyclophosphamide (CTX)-treated rats via the delivery of miR-144-5p, which can be transferred to cocultured CTX-damaged granulosa cells (GCs) to decrease GC apoptosis. A functional assay revealed that overexpression of miR-144-5p in BMSCs showed efficacy against CTX-induced POF, and the improvement in the repair was related to the inhibition of GC apoptosis by targeting PTEN. The opposite effect was exhibited when miR-144-5p was inhibited. Taken together, our experimental results provide new information regarding the potential of using exosomal miR-144-5p to treat ovarian failure.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31537899 DOI: 10.1038/s41374-019-0321-y
Source DB: PubMed Journal: Lab Invest ISSN: 0023-6837 Impact factor: 5.662